Apogee Therapeutics (APGE) director granted options for 7,657 shares at $85

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Apogee Therapeutics director William A. Jones Jr received a grant of stock options giving him the right to buy 7,657 shares of Apogee common stock at an exercise price of $85.0000 per share. These options were awarded as compensation, not purchased in the open market, and expire on June 9, 2036. The award will fully vest on the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. After this grant, he directly holds options covering 7,657 underlying shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider JONES WILLIAM A JR

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,657	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 7,657 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 7,657 shares Exercise price: $85.0000 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 7,657 shares Underlying common stock in new option award

Exercise price $85.0000 per share Stock option exercise price

Expiration date June 9, 2036 Option award expiry

Shares following transaction 7,657 derivative shares Total options held after grant

Vesting schedule 100% after one year Vests on one-year anniversary of grant if service continues

Key Terms

Stock Option (Right to Buy), exercise price, Common Stock, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 85.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"will vest on the one-year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/11/2026 - 08:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES WILLIAM A JR

(Last)

(First)

(Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$85	06/09/2026		A		7,657		⁽¹⁾	06/09/2036	Common Stock	7,657	$0.00	7,657	D

Explanation of Responses:

1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for William Jones	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for William A. Jones Jr?

Apogee Therapeutics reported that director William A. Jones Jr received a stock option grant covering 7,657 shares. The options are a compensation award, not an open-market purchase, and give him the right to buy Apogee common stock at a fixed exercise price.

How many Apogee Therapeutics (APGE) shares are covered by the new option grant?

The new option grant to William A. Jones Jr covers 7,657 underlying shares of Apogee Therapeutics common stock. This entire amount was awarded in a single transaction dated June 9, 2026, and represents his reported direct derivative holdings after the grant.

What is the exercise price and expiration date of the APGE stock options granted?

The granted stock options have an exercise price of $85.0000 per share and expire on June 9, 2036. This lets the director buy Apogee common stock at that fixed price any time before expiration, subject to the options vesting and other plan terms.

When do the newly granted Apogee Therapeutics (APGE) options vest?

The options granted to William A. Jones Jr will vest on the one-year anniversary of the grant date. Vesting is conditional on his continued service with Apogee Therapeutics through that vesting date, meaning the award is designed to encourage ongoing board service.

Was the APGE insider transaction a market purchase or a compensation award?

The APGE insider transaction was a compensation-related award, not a market purchase. The Form 4 classifies it as a grant or other acquisition of stock options, with no cash price paid per option on the grant date and an exercise price set at $85.0000 per share.